Press Releases

Press Releases

Date Title & Summary Additional Formats
09/09/14
Cidara Therapeutics to Present Data from Antifungal Drug Development Program at ICAAC
Results from nonclinical studies of Cidara’s lead candidate CD101 IV (formerly biafungin), a novel, long-acting echinocandin, will be presented this week at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) meeting in Washington D.C.
06/30/14
Cidara Completes $32M Series A Financing
Veteran team to apply novel, small molecule immunotherapy platform to treat severe fungal infections in immune compromised patients. Cidara has completed a $32 million Series A financing that will enable it to advance candidates from the company’s Cloudbreak™ targeted immunotherapy platform and